tag one-medical-group 
PharmaShots
JUNE 23, 2023
Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)
PharmD Live
DECEMBER 21, 2021
With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag. Medications approved in 2021 for chronic care: PharmD Live’s Chronic Care Medication Update Webinar covers the latest FDA-approved medications. See it here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
epicur
DECEMBER 7, 2023
Analyze information from your practice management system, past caseloads, your purchase history, and the corresponding medical supplies, medications, and equipment required. New medications or procedures may impact your inventory requirements. Experiencing shortened beyond-use dates on compounded medication?
pharmaphorum
AUGUST 17, 2020
N o one industry is ever quite like another, but there are some valuable lessons for pharma marketing from examining how the financial sector uses technology, builds brands on social channels and approaches digital content. As a result there is a huge demand for trustworthy content.
PharmD Live
JANUARY 25, 2022
Chronic care services managed by a doctor of pharmacy, PharmD, is a critical addition to a medical practice, but they are not widely engaged with these responsibilities. Like many physicians, he prescribes around 300 medications regularly and with a great deal of comfort knowing their mechanism of action, interactions, and side effects.
pharmaphorum
DECEMBER 23, 2022
This alone causes expense for cash-strapped hospitals and puts pressure on nursing and medical staff while they manage the side effects. Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. Side effects and cost implications.
pharmaphorum
JANUARY 21, 2022
Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone. Medical science is accelerating at a tremendous rate, leading to profound changes in the treatment landscape for many diseases over the last decade. “It About the author.
Expert insights. Personalized for you.
40 
Let's personalize your content